Subtopic Deep Dive
RB1 Mutations in Retinoblastoma
Research Guide
What is RB1 Mutations in Retinoblastoma?
RB1 mutations cause biallelic inactivation of the RB1 tumor suppressor gene, initiating retinoblastoma through germline or somatic mechanisms with defined genotype-phenotype correlations.
Retinoblastoma arises from RB1 loss, with germline mutations causing bilateral tumors and somatic mutations leading to unilateral cases (Dimaras et al., 2012; 639 citations). High-risk features include 13q deletions increasing secondary malignancy risk (Hansen et al., 1985; 419 citations). Over 10 key papers document RB1's role, from protein interactions to therapy targets.
Why It Matters
RB1 testing identifies heritable cases for family screening and intensified surveillance, reducing second cancers like osteosarcoma (Hansen et al., 1985). Genotype guides treatment: germline carriers require genetic counseling and enucleation considerations (Dimaras et al., 2015; 522 citations). Genomic analyses reveal epigenetic vulnerabilities for novel therapies, improving survival beyond 95% in developed regions (Zhang et al., 2012; 506 citations). Array CGH detects 13q losses predicting poor outcomes.
Key Research Challenges
RB1-Negative Retinoblastomas
10-15% of tumors lack RB1 mutations, complicating diagnosis and prognosis (Rushlow et al., 2013; 406 citations). These cases show distinct genomic and expression profiles requiring alternative markers. Clinical studies urge integrated multi-omics for accurate classification.
Post-RB1 Progression Mechanisms
Tumors advance rapidly after RB1 loss via p53 pathway inactivation (Laurie et al., 2006; 584 citations). MYCN amplification and epigenetic changes drive this, but timing and interactions remain unclear. Therapies targeting these are underdeveloped.
Genotype-Phenotype Correlations
Specific RB1 mutations correlate variably with extraocular spread and metastasis risk (Dimaras et al., 2015). 13q deletions worsen outcomes, yet predictive models lack precision (Hansen et al., 1985). Large cohort sequencing is needed for counseling accuracy.
Essential Papers
The Human Papilloma Virus-16 E7 Oncoprotein Is Able to Bind to the Retinoblastoma Gene Product
Nicholas J. Dyson, Peter M. Howley, Karl Münger et al. · 1989 · Science · 3.0K citations
Deletions or mutations of the retinoblastoma gene, RB1, are common features of many tumors and tumor cell lines. Recently, the RB1 gene product, p105-RB, has been shown to form stable protein/prote...
Retinoblastoma
Helen Dimaras, Kahaki Kimani, E Dimba et al. · 2012 · The Lancet · 639 citations
Inactivation of the p53 pathway in retinoblastoma
Nikia A. Laurie, Stacy L. Donovan, Chie-Schin Shih et al. · 2006 · Nature · 584 citations
A novel retinoblastoma therapy from genomic and epigenetic analyses
Jinghui Zhang, Claudia A. Benavente, Justina McEvoy et al. · 2012 · Nature · 506 citations
Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated by the biallelic loss of RB1. Tumours progress very quickly following RB1 inactivation but the underlying...
Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein.
Stephen Friend, Jordan M. Horowitz, Monica Gerber et al. · 1987 · Proceedings of the National Academy of Sciences · 430 citations
Retinoblastoma is a childhood tumor that can arise because of mutant alleles acquired as somatic or germinal mutations. The mutant allele can be carried in the germ line. The mutations creating the...
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition.
Mark Hansen, Alex Koufos, Brenda L. Gallie et al. · 1985 · Proceedings of the National Academy of Sciences · 419 citations
Survivors of the heritable form of retinoblastoma subsequently develop second primary osteosarcomas at substantially greater frequency than either the general population or survivors of nonheritabl...
<i>RB1</i>: a prototype tumor suppressor and an enigma
Nicholas J. Dyson · 2016 · Genes & Development · 414 citations
The retinoblastoma susceptibility gene ( RB1 ) was the first tumor suppressor gene to be molecularly defined. RB1 mutations occur in almost all familial and sporadic forms of retinoblastoma, and th...
Reading Guide
Foundational Papers
Start with Dyson et al. (1989; 3044 citations) for RB1 protein interactions, Friend et al. (1987; 430 citations) for gene deletions, and Hansen et al. (1985; 419 citations) for heritable risks—these establish RB1 as the first tumor suppressor.
Recent Advances
Study Dimaras et al. (2015; 522 citations) for comprehensive genetics, Rushlow et al. (2013; 406 citations) for RB1-negative tumors, and Dyson (2016; 414 citations) for suppressor functions.
Core Methods
Array CGH detects deletions (Hansen 1985), whole-genome sequencing reveals epigenetics (Zhang 2012), and protein binding assays confirm inactivation (Dyson 1989); integrate with p53 pathway analysis (Laurie 2006).
How PapersFlow Helps You Research RB1 Mutations in Retinoblastoma
Discover & Search
Research Agent uses searchPapers for 'RB1 germline mutations retinoblastoma' yielding Dimaras et al. (2015; 522 citations), then citationGraph maps 430-citation Friend et al. (1987) connections, and findSimilarPapers uncovers Rushlow et al. (2013) on RB1-negative cases. exaSearch scans 250M+ OpenAlex papers for 13q deletion studies.
Analyze & Verify
Analysis Agent applies readPaperContent to Zhang et al. (2012) abstract on epigenetic therapy, verifies mutation frequencies via runPythonAnalysis on citation data (pandas aggregation of 500+ RB1 papers), and uses verifyResponse (CoVe) with GRADE grading to confirm p53 inactivation claims from Laurie et al. (2006). Statistical verification quantifies genotype risks.
Synthesize & Write
Synthesis Agent detects gaps in RB1-negative therapies via contradiction flagging across Rushlow (2013) and Dimaras (2015), while Writing Agent uses latexEditText for genotype-phenotype tables, latexSyncCitations for 10 foundational papers, and latexCompile for review drafts. exportMermaid diagrams RB1 inactivation pathways.
Use Cases
"Analyze mutation frequencies in 100+ retinoblastoma cohorts from papers."
Research Agent → searchPapers('RB1 mutation frequency retinoblastoma') → Analysis Agent → runPythonAnalysis(pandas on extracted data from Dimaras 2012/2015) → CSV export of aggregated germline vs somatic rates with stats.
"Draft LaTeX review on RB1 genotype-phenotype correlations."
Synthesis Agent → gap detection (13q risks) → Writing Agent → latexEditText(manuscript) → latexSyncCitations(Dimaras 2015, Hansen 1985) → latexCompile → PDF with cited figures.
"Find code for RB1 sequencing analysis in retinoblastoma papers."
Research Agent → paperExtractUrls(Zhang 2012 genomic analysis) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Verified pipelines for variant calling and epigenetic modeling.
Automated Workflows
Deep Research workflow scans 50+ RB1 papers via searchPapers → citationGraph → structured report on mutation spectra (Dimaras 2015 benchmark). DeepScan's 7-step chain analyzes Rushlow (2013) with readPaperContent → CoVe verification → Python stats on RB1-negative genomics. Theorizer generates hypotheses on p53-RB1 interactions from Laurie (2006) and Dyson (2016).
Frequently Asked Questions
What defines RB1 mutations in retinoblastoma?
RB1 mutations inactivate both alleles of the RB1 gene, causing germline (bilateral) or somatic (unilateral) retinoblastoma (Friend et al., 1987; Dyson, 2016).
What methods detect RB1 mutations?
Sequencing, array CGH for 13q deletions, and protein assays identify mutations; integrate with expression profiling for RB1-negative cases (Rushlow et al., 2013; Zhang et al., 2012).
What are key papers on RB1?
Dyson et al. (1989; 3044 citations) shows E7 binding; Dimaras et al. (2015; 522 citations) reviews clinical genetics; Zhang et al. (2012; 506 citations) links to therapies.
What open problems exist?
Mechanisms of RB1-independent tumors, precise secondary cancer risk models, and targeted therapies post-p53 loss remain unsolved (Rushlow et al., 2013; Laurie et al., 2006).
Research Ocular Oncology and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching RB1 Mutations in Retinoblastoma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Ocular Oncology and Treatments Research Guide